ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Prednisone

Also written as “prednisone”, “CHOP” and “Lodotra®”.

Its studies are mostly in Prostatic Neoplasms · Lymphoma, Large B-Cell, Diffuse · Arthritis, Rheumatoid · Lymphoma, T-Cell, Peripheral · Asthma, led by 13 companies.

Drug pagePrednisone: every studyMany companies study it; this page follows only the 26 they lead. All 547 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Nov 1, 199926 company-led studies, 3 open or runningNext primary completion: Feb 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizerits history only40 open or runningphase 3since Nov 1, 1999Nov 1, 1999none ahead
Sanofiits history only40 open or runningphase 4since Jul 20, 2012Mar 3, 2011none ahead
Bristol-Myers Squibbits history only30 open or runningphase 2since Apr 19, 2007Apr 19, 2007none ahead
Takedaits history only31 open or runningphase 3since Jul 25, 2007Jul 25, 2007none ahead
Boehringer Ingelheimits history only20 open or runningphase 4since Jul 8, 2014Jul 8, 2014none ahead
Eli Lillyits history only21 open or runningphase 2since May 11, 2020May 11, 2020Feb 2027phase 2 · NCT04411654
Mundipharmaits history only20 open or runningphase 4since Feb 14, 2014Mar 14, 2013none ahead
Amgenits history only10 open or runningphase 2since May 26, 2008May 26, 2008none ahead
Ampel BioSolutionsits history only10 open or runningphase 4since Mar 21, 2017Mar 21, 2017none ahead
CareDxits history only11 open or runningno phasesince Oct 21, 2026Oct 21, 2026Dec 2028NCT07905599
Sumitomo Pharma10 open or runningphase 1since Dec 7, 2020Dec 7, 2020none ahead

Also a collaborator on its studies: AbbVie, Basilea Pharmaceutica International and Shionogi.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sumitomo Pharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 7, 2020First study: phase 1 study in Metastatic Castration-Resistant Prostate CancerFirst studyNCT04666129 · 48 enrolled · United States

TargetBeta

NR3C1 →read by rule
“Glucocorticoid receptor agonist”ChEMBL 37, by rule

Other programs on NR3C1

ProgramCompanyFurthest phaseStudies
DexamethasoneruleAbbViephase 4174
BudesonideruleAstraZenecaphase 4167
fluticasone furoateruleGlaxoSmithKlinephase 497
BeclomethasoneruleChiesi Farmaceuticiphase 446
PrednisoloneruleSanofiphase 434
betamethasone dipropionateruleLEO Pharmaphase 427
MethylprednisolonerulePfizerphase 423
dexamethasone phosphateruleeyegate-pharmaceuticals-incphase 421
BetamethasoneruleLEO Pharmaphase 49
Triamcinoloneruleresearch-insight-llcphase 45
relacorilantruleCorcept Therapeuticsphase 322
Triamcinolone Acetonideruleclearside-biomedical-incphase 320

Studies

The one study Sumitomo Pharma leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04666129Metastatic Castration-Resistant Prostate Cancer · United States1CompletedMay 28, 202448

How it is read

Names in the registry

  • “Prednisone”, 39 entries
  • “prednisone”, 7 entries
  • “CHOP”, 2 entries
  • “Lodotra®”, 2 entries
  • “Abiraterone/prednisone”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.